Cervical Cancer Animation / Cervical Cancer Illustrations

'Urgent Need' For HPV Vaccine In Developing World, Opinion Piece Says
While officials in the United Kingdom and the U.S. are "dithering and doubting" over issues related to GlaxoSmithKline and Merck's HPV vaccines, "there is an urgent need" for Gardasil and Cervarix in developing countries, Sarah Boseley -- health editor at London's

Higher Risk Of Certain Cancers Being Recorded In HIV-Positive People
Physicians in the U.S. are reporting a higher risk for certain types of cancers -- such as liver, head, neck and lung -- in people living with HIV/AIDS, raising concerns that a cancer epidemic is imminent in the population, the Baltimore Sun reports. According to the Sun, Meredith Shiels, a doctoral candidate at the

Mexican Department Of Public Health To Launch Screening For Papillomavirus, Cause Of Cervical Cancer
In a campaign to significantly reduce the most common cancer affecting Mexican women, the Mexican Public Health Agency (Secretaria de Salud) announced that it is launching the first phase of a program that will offer free testing for human papillomavirus (HPV), the primary cause of cervical cancer, to all low-income women age 35-65.

Case Strengthens For HPV Vaccination In Boys
Latest results from a clinical trial of Gardisalâ„¢, the Australian developed vaccine for human papilloma virus, add to the growing weight of opinion that the Government should extend its funding of the vaccine to boys. The research was presented today (18/11) to the Clinical Oncolgoical Society of Australia Annual Scientific Meeting in Sydney.

South African Advocacy Group Calls For Increased HPV Vaccinations Of HIV-Positive Women
The Treatment Action Campaign of South Africa is calling on pharmaceutical companies to "dramatically lower the prices" of human papillomavirus vaccines to make them more affordable for HIV-positive women, the Cape Times/IOL reports.

Four-type HPV Vaccine Gardasil(R) Is Also Effective In Men
The four-type (6,11,16,18) human papillomavirus (HPV) vaccine GardasilÂ® is also effective in men according to the primary analysis from a pivotal phase III clinical study. In previously uninfected men aged 16 to 26 years*, GardasilÂ® prevented 90% (95%CI: 69, 98) of external genital lesions caused by HPV types 6, 11, 16 or 18. The data were presented this week at the congress of the European Research Organisation on Genital Infection and Neoplasia (EUROGIN) in Nice, France.

New Research Shows Knowledge Of HPV And Vaccination Could Improve Cervical Screening Attendance
Information about vaccination against the virus that causes cervical cancer could encourage rather than discourage women to attend for cervical screening, a new survey has found.1 A number of commentators have said that vaccinating women against the human papillomavirus (HPV), which causes cervical cancer, could make them complacent about attending for cervical screening (smear test), although to date there has been no evidence to support this.

New Data On Cancer Diagnostic Presented By Arbor Vita
Arbor Vita Corporation (AVC), a privately held biopharmaceutical company, presented new data on its rapid, point-of-care prototype HPV test with a high positive predictive value for cervical cancer and pre-cancer. Targeted for use throughout the developing world, this diagnostic test is being developed in partnership with PATH.

GARDASIL(R) Demonstrated Efficacy In Preventing HPV-Related Disease In Males In Phase III Study
GARDASILÂ® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant], the cervical cancer vaccine from Merck & Co., Inc., prevented 90 percent of external genital lesions caused by human papillomavirus (HPV) types 6, 11, 16 and 18 in a pivotal Phase III study in men aged 16 to 26.

Researchers Say Identification Of Women With HPV Types 16, 18 And 45 Could Improve Early Intervention To Stop Cervical Cancer
As testing for high-risk types of the human papillomavirus (HPV) emerges as the gold standard in cervical cancer prevention, scientists are already researching how to determine even more precisely who is most likely to develop the disease and thus are in need of more immediate intervention.

Study Finds HPV Vaccine Gardasil Effective At Preventing Male Genital Lesions
Merck's human papillomavirus vaccine Gardasil is about 90% effective in preventing external lesions -- mostly gential warts -- caused by the four HPV strains it targets and 45% effective in preventing HPV infection, according to a Merck-funded study, Reuters reports (Fox, Reuters, 11/12).

Modelling Research Shows CervarixTM-induced Immune Response May Be Prolonged For At Least 20 Years For Both HPV 16 And 18
Results of three statistical models presented today at the European Research Organisation on Genital Infection and Neoplasia (EUROGIN) annual meeting in Nice, France, suggest that young women vaccinated with GlaxoSmithKline's cervical cancer vaccine CervarixTM could look forward to a prolonged immune response against the two most common cancer-causing human papillomavirus virus (HPV) types, HPV 16 and 18 for at least 20 years.

Hologic Releases The Results Of The Cervista(TM) HPV Clinical Trials
Hologic, Inc. (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced the results of the Cervista HPV high-risk pivotal clinical trial. The Cervista HPV high-risk test is currently under review by the FDA in the U.S. and is expected to be launched in the European Union (EU) early in 2009.

Making HPV Vaccination Mandatory Is Unwarranted And Unwise
The HPV vaccine, sold as Gardasil in the U.S., is intended to prevent four strains of the human papillomavirus, the most common sexually transmitted infection in the world. The vaccine also prevents against cervical cancer. While the vaccine represents a significant public health advance, a new article in the Journal of Law, Medicine & Ethics suggests that it is premature for states to currently mandate the HPV vaccine as a condition for school attendance. Gail Javitt, J.D.

LSUHSC Public Health Contributes To Estimate Of HPV-Related Cancers
Professor Vivien Chen, PhD,. Associate Professor Xiao Cheng Wu, MD, PhD and Assistant Professor Edward Peters, DMD, SM, ScD, at LSU Health Sciences Center New Orleans School of Public Health contributed five papers to the largest most comprehensive assessment of the burden of human papillomavirus (HPV)-associated cancers in the United States to date.

Cervical Cancer Animation / Cervical Cancer Illustrations

Human Papillomavirus Animations (HPV Animation / HPV Illustrations)

Vaccine Animations / Vaccine Illustrations- Human Papillomavirus illustrations

Human papillomavirus animation and human papillomvirus illustrations


Medical Animation \| Mechanism of Action \| Medical Print Illustration \| Holo 3D \| General 3D \| Contact